Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.
Satish S C RaoXuelian XiangYun YanKulthep RattanakovitTanisa PatcharatrakulRachael ParrDeepak AyyalaAmol SharmaPublished in: Alimentary pharmacology & therapeutics (2020)
Linaclotide prolongs afferent gut-brain signalling from baseline but both afferent and efferent signalling were unaffected compared to placebo. Linaclotide significantly improves rectal hypersensitivity, IBS-C symptoms and QOL compared to placebo. These mechanisms may explain the effects of linaclotide on pain relief in IBS-C patients. ClinicalTrials.Gov: Registered at Clinical trials.gov no NCT02078323.
Keyphrases
- clinical trial
- double blind
- phase iii
- open label
- placebo controlled
- phase ii
- end stage renal disease
- newly diagnosed
- white matter
- study protocol
- irritable bowel syndrome
- ejection fraction
- resting state
- cerebral ischemia
- randomized controlled trial
- neuropathic pain
- peritoneal dialysis
- rectal cancer
- spinal cord injury
- sleep quality
- blood brain barrier